These drugs have the potential to impact various aspects of the industry, as an individual weighing around 200 pounds and wearing size 2X could lose 15% to 22.5% of their body weight with their help.

So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so.” Based on SURMOUNT-5 results released last month, Zepbound was more effective in promoting weight ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027. Patients who are more obese may ultimately do better with Zepbound, said ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Off-brand copies of the GLP-1 drugs were used during a shortage of Zepbound and Mounjaro. REUTERS. The FDA permits compounded versions of brand name drugs when they are in shortage, and the shift ...

So, Zepbound is expected to take the lead in the obesity market if it hasn’t already done so.” Based on SURMOUNT-5 results released last month, Zepbound was more effective in promoting weight ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...